In this review:
Lung Cancer
First-line treatment of EGFR-mutant NSCLC
Erlotinib vs. docetaxel in wild-type EGFR NSCLC
Phase III PARAMOUNT study – final OS results
First-in-human study of ALK inhibitor
LDK378 Optimal timing of TRT
Breast Cancer
Phase III EMI
Please login below to download this issue (PDF)